WaveMan · Form 4
Mubadala Investment Co PJSC insider trades
> Search tickers & screens ⌘K
LIVE

Mubadala Investment Co PJSC insider trades

Mubadala Investment Co PJSC has filed 12 Form 4s with the SEC that we hold, for Recursion Pharmaceuticals, INC. (RXRX) (10% owner), CIK 2006758 (10% owner) and EDR (Reporting owner). Across all of them we count 10 purchases worth $64.9M and 0 sales worth $0 reported on Form 4. None of these purchases or sales is dated in the last 12 months. The largest single trade was a purchase of 1,667,108 shares of CIK 2006758 worth $43.3M, dated 2024-06-14. The first filing on our record is dated 2022-10-31 and the latest 2025-09-11.

Recursion Pharmaceuticals, INC. (RXRX)

10% owner · 9 filings · 8 purchases and sales
Trade dateCodeSharesValue as filedFiled
2023-02-01P, purchase reported on Form 4600$4.8K2023-02-02
2023-02-13P, purchase reported on Form 432,474$258.8K2023-02-14
2023-02-17P, purchase reported on Form 463,382$488.7K2023-02-21
2023-02-24P, purchase reported on Form 4109,118$833.7K2023-02-27
2023-02-27P, purchase reported on Form 452,500$403.7K2023-02-28
2023-02-28P, purchase reported on Form 4815$6.5K2023-03-01
2023-03-01P, purchase reported on Form 448,867$388.0K2023-03-02
2023-03-02P, purchase reported on Form 466,822$522.5K2023-03-03

CIK 2006758

10% owner · 2 filings · 2 purchases and sales
Trade dateCodeSharesValue as filedFiled
2024-06-14P, purchase reported on Form 41,667,108$43.3M2025-09-11
2025-07-29P, purchase reported on Form 4773,328$18.7M2025-07-31

EDR

Reporting owner · 1 filing · 0 purchases and sales

No purchase or sale of common stock reported here; these filings cover grants, option exercises or other codes.

Source

Counted from the Form 4 filings this reporting owner (SEC CIK 1704268) filed on EDGAR. Values are the transaction values as filed. See every filing on EDGAR, or browse insider buying and today's insider purchases.

Source: U.S. Securities and Exchange Commission (EDGAR) and other official government data · Updated 2026-10-12 · For informational purposes only, not investment advice.
Privacy · Terms